DE69923982D1 - Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten - Google Patents

Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten

Info

Publication number
DE69923982D1
DE69923982D1 DE69923982T DE69923982T DE69923982D1 DE 69923982 D1 DE69923982 D1 DE 69923982D1 DE 69923982 T DE69923982 T DE 69923982T DE 69923982 T DE69923982 T DE 69923982T DE 69923982 D1 DE69923982 D1 DE 69923982D1
Authority
DE
Germany
Prior art keywords
indomethacin
angiotensin
composition containing
preparites
glomerulonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69923982T
Other languages
English (en)
Other versions
DE69923982T2 (de
Inventor
Remi Brouard
Giuseppe Remuzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE69923982D1 publication Critical patent/DE69923982D1/de
Application granted granted Critical
Publication of DE69923982T2 publication Critical patent/DE69923982T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69923982T 1998-07-10 1999-07-08 Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten Expired - Lifetime DE69923982T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9808976A FR2780890B3 (fr) 1998-07-10 1998-07-10 Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour le traitement des glomerulonephrites chroniques
FR9808976 1998-07-10
PCT/FR1999/001650 WO2000002556A1 (fr) 1998-07-10 1999-07-08 Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques

Publications (2)

Publication Number Publication Date
DE69923982D1 true DE69923982D1 (de) 2005-04-07
DE69923982T2 DE69923982T2 (de) 2006-03-30

Family

ID=9528595

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923982T Expired - Lifetime DE69923982T2 (de) 1998-07-10 1999-07-08 Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten

Country Status (6)

Country Link
EP (1) EP1115399B1 (de)
AT (1) ATE289811T1 (de)
AU (1) AU4625299A (de)
DE (1) DE69923982T2 (de)
FR (1) FR2780890B3 (de)
WO (1) WO2000002556A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1960355A1 (de) 2005-11-30 2008-08-27 F.Hoffmann-La Roche Ag 3-amino-1-arylpropylindole und aza-substituierte indole
DE602006009138D1 (de) 2005-11-30 2009-10-22 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon

Also Published As

Publication number Publication date
EP1115399A1 (de) 2001-07-18
FR2780890B3 (fr) 2000-09-01
WO2000002556A1 (fr) 2000-01-20
FR2780890A1 (fr) 2000-01-14
ATE289811T1 (de) 2005-03-15
EP1115399B1 (de) 2005-03-02
DE69923982T2 (de) 2006-03-30
AU4625299A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BR0110028A (pt) Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica
TR200000913T2 (tr) Tıbbi maddeler
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
IL142047A0 (en) Mglur5 antagonists for the treatment of pain and anxiety
DE60332011D1 (de) Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE69923982D1 (de) Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
MX2007004461A (es) Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico.
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE353886T1 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

R082 Change of representative

Ref document number: 1115399

Country of ref document: EP

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE